MiRus locks in $1.5B strategic round, hits $4.41B valuation

MiRus, a cardiovascular and orthopedic medical device company, has closed a $1.5 billion late-stage funding round anchored by Boston Scientific. The deal structure includes Boston Scientific investing $1.5 billion for a 34% stake in MiRus, along with an option related to MiRus’s transcatheter aortic valve replacement (TAVR) system, according to recent analyst coverage. This transaction brings MiRus’s post-money valuation to approximately $4.41 billion and pushes the company firmly into unicorn territory, with more than $1 billion raised to date, based on PitchBook data referenced in multiple reports.

The round is positioned as a strategic investment rather than a traditional venture Series round, reflecting Boston Scientific’s intent to strengthen its structural heart and advanced orthopedic implant portfolio by closely aligning with MiRus’s technology pipeline. Industry trackers now rank MiRus among the top-valued new unicorns of 2026, noting that its valuation surge was driven by this single major transaction. The company focuses on cardiovascular and orthopedic devices, and the new capital and strategic backing are expected to support commercialization of its TAVR system and broader expansion of its advanced implant technologies. This investment also underscores growing investor appetite for late-stage, non-AI HealthTech plays amid a broader unicorn boom that has otherwise been dominated by artificial intelligence companies.